Lo Menzo S, Biagi E, Di Nuzzo M, Grilli A, Contini C

Language: English
References: 15
Page: 661-664
PDF size: 125.76 Kb.

ABSTRACT

Directly-acting antivirals (DAA) have changed the chronic hepatitis C virus (HCV) infection therapeutic scenario allowing virus eradication in more than 95% of patients, independently from the genotype, with 12 to 24-week treatment regimens. We describe a 51- year-old Pakistani man with a chronic HCV-genotype 3 (GT3a) infection with moderate liver fibrosis, who achieved sustained virological response (SVR) 24 after a tripled dose of Daclatasvir (DCV) taken erroneously associated to Sofosbuvir (SOF). The patient had a concomitant intestinal TB infection whose treatment had been delayed in order to firstly eradicate HCV to reduce the liver toxicity of anti-mycobacterial drugs. Thanks to the cultural mediator support, we explained to the patient the correct posology of each drug to take during the day consisting of 12 week SOF (400 mg daily) plus DCV (60 mg daily) regimen. He returned 13 days after for a programmed visit and we were surprised to learn that he had taken 3 pills of DCV (180 mg/daily) instead of one, thus ending DCV assumption after only 9 days while SOF was taken correctly. He complained no symptoms. We immediately performed blood test that showed alteration of lactate dehydrogenase, creatine phosphokinase, and creatin kinase MB activity. At day 15 we stopped SOF closely monitoring the patient. Blood test alterations returned normal after one week of treatment suspension, HCV viremia remained suppressed after 4, 12 and 24 weeks proving HCV eradication. If confirmed, these data could suggest that higher doses of DCV, if tolerated, might be employed in short-time HCV-GT3 treatment.

REFERENCES

1. D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Directacting antivirals: the endgame for hepatitis C? Curr Opin Virol 2017; 24: 31-37. doi: 10.1016/j.coviro.2017.03.017.

2. EASL Recommendations on Treatment of Hepatitis C 2016. European Association for the Study of the Liver. J Hepatol 2017; 66:153-194. doi: 10.1016/j.jhep.2016.09.001.

3. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22: 7824-40. doi: 10.3748/wjg.v22.i34.7824.

4. Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, et al. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis 2014; 14(Suppl. 5): S2. doi: 10.1186/1471-2334-14-S5-S2.

5. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, et al. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35.

6. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18:e516-22. doi: 10.1111/j.1365-2893.2011.01441.x.

7. Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus- Genotype 3: update on current and emergent therapeutic interventions. Curr Infect Dis Rep 2017; 19: 22. doi: 10.1007/ s11908-017-0578-5.

8. Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 2016; 7: 33-40. doi: 10.4292/ wjgpt.v7.i1.33.

9. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; 65: 1861-70. doi: 10.1136/gutjnl-2016-312444.

10. Sulkowski MS, Flamm S, Kayali Z, Lawitz EJ, Kwo P, McPhee F, Torbeyns A, et al. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver Int 2017; 37: 836- 842. doi: 10.1111/liv.13335.

11. Mangia A, Santoro R, Piattelli M, Leandro G, Minerva N, Annese M, Bacca D, et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol 2002; 37: 109-16.

12. Hasson H, Messina E, Merli M, Della Torre L, Morsica G, Bagaglio S, Lazzarin A. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/ HCV co-infected cirrhotic woman. Int J Infect Dis 2014; 29: 100-2. doi: 10.1016/j.ijid.2014.08.011.

13. Lawitz E, Poordad F, Gutierrez JA, Wells JT, Landaverde CE, Evans B, Howe A, et al. Short-duration treatment with elbasvir/ grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology 2017; 65: 439-50. doi: 10.1002/ hep.28877.

14. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373: 714-25. doi: 10.1056/NEJMoa1503153.

15. Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, et al. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. J Clin Virol 2015; 32-5. doi: 10.1016/ j.jcv.2015.10.010.